UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy SABR Dose Constraints

Gerard Hanna, Lousie Murray, Rushil Patel, Suneil Jain, Katharine Aitken, Kevin Franks, Nicholas van As, Alison Tree, Paul Hatfield, Stephen Harrow, Fiona McDonald, Merina Ahmed, Frank Saran, Gareth Webster, Vincent Khoo, David Landau, David Eaton, Maria Hawkins

Research output: Contribution to journalArticle

41 Citations (Scopus)
1264 Downloads (Pure)

Abstract

6 UK studies investigating SABR are currently open. Many of these involve treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk (OAR) dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will permit meaningful toxicity comparisons between SABR studies and internationally.
Original languageEnglish
Number of pages10
JournalClinical Oncology
Early online date13 Oct 2017
DOIs
Publication statusEarly online date - 13 Oct 2017

Keywords

  • SABR
  • Stereotactic
  • SBRT
  • Dose Constraints
  • Radiotherapy
  • UK

Fingerprint Dive into the research topics of 'UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy SABR Dose Constraints'. Together they form a unique fingerprint.

  • Cite this

    Hanna, G., Murray, L., Patel, R., Jain, S., Aitken, K., Franks, K., van As, N., Tree, A., Hatfield, P., Harrow, S., McDonald, F., Ahmed, M., Saran, F., Webster, G., Khoo, V., Landau, D., Eaton, D., & Hawkins, M. (2017). UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy SABR Dose Constraints. Clinical Oncology. https://doi.org/10.1016/j.clon.2017.09.007